GlassScriptPhysician profile
Anthony Costales
NPI 1578828703
$16,742.54
in general payments reported to CMS, 2019-2025
14 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $3,450 · 2021: $1,950 · 2022: $323 · 2023: $8,027 · 2024: $2,292 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,845 · Food and Beverage: $1,261 · Travel and Lodging: $523 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,845.00 |
| Food and Beverage | $1,261.43 |
| Travel and Lodging | $523.29 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $9,725.64 | 2022-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $3,515.96 | 2020-2025 | Enhertu |
| Glaxosmithkline, LLC. | $2,172.53 | 2021-2022 | |
| Tesaro, INC. | $294.32 | 2019 | |
| Abbvie INC. | $198.81 | 2024-2025 | |
| Eisai INC. | $159.66 | 2022-2025 | |
| Genmab U.S., INC. | $136.04 | 2023-2025 | Tivdak |
| Immunogen, INC. | $132.78 | 2023 | Elahere |
| On Target Laboratories, INC | $118.80 | 2025 | Cytalux |
| Hologic Sales and Service, LLC | $118.05 | 2023 | Coolseal Generator, Acessa Provu System |
| Daiichi Sankyo INC. | $54.69 | 2025 | Datroway, Enhertu |
| Clovis Oncology, INC. | $52.39 | 2019 | |
| Stryker Corporation | $42.59 | 2022 | |
| Intuitive Surgical, INC. | $20.28 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Costales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.